



# HELP IMPROVE TREATMENTS FOR MERKEL CELL CARCINOMA

## *Participate in a clinical trial*

The GoTHAM Trial is testing the immunotherapy drug Avelumab in combination with either radionuclide therapy or external beam radiotherapy.

The Australia-wide trial aims to enrol **65 participants** with **metastatic Merkel cell carcinoma** in all capital cities.

### **Am I eligible?**

To be eligible, you must be 18 years or older, have **metastatic Merkel cell carcinoma** and normal organ function. Additional criteria apply.

### **What's involved in the trial?**

If eligible, you will receive either Avelumab and radiotherapy (EBRT); or Avelumab and PRRT (LuTate) and be reviewed for up to 24 months. In addition to your healthcare team's treatment and monitoring, you will have trial assessments to monitor your safety and treatment progress. Additional assessments apply.

### **Why should I join this trial?**

By participating in this trial, you may be helping researchers to develop a well-tolerated and effective immunotherapy combination to further improve disease control and overall survival for patients with metastatic Merkel cell carcinoma.

### **Where can I join this trial?**

The GoTHAM trial is currently recruiting at six sites in Australia:

**Peter MacCallum Cancer Centre** (VIC)

**Princess Alexandra Hospital** (QLD)

**Royal Brisbane and Women's Hospital** (QLD)

**Royal North Shore Hospital** (NSW)

**Royal Adelaide Hospital** (SA)

**Sir Charles Gairdner Hospital** (WA)

## **ASK YOUR DOCTOR ABOUT GoTHAM**

Email [gotham@masc.org.au](mailto:gotham@masc.org.au) or visit [masc.org.au/gotham](http://masc.org.au/gotham)